How Much Does Farxiga (Dapagliflozin) Cost in Delaware in 2026?

Delaware Cash-Pay Price for Farxiga in 2026

Without insurance, Farxiga costs around $620 per month at most Delaware retail pharmacies. That figure tracks the AstraZeneca wholesale acquisition cost (WAC) and does not vary much between Walgreens, CVS, or independent pharmacies across the state. There is no generic version of dapagliflozin on the U.S. Market as of mid-2026.

Why the Cash Price Stays High

Farxiga is still under patent protection, giving AstraZeneca exclusive pricing authority. The FDA-approved prescribing information lists dapagliflozin in 5 mg and 10 mg tablet strengths, both priced identically. Patent expiry dates suggest generic competition may not arrive before 2028 at the earliest.

How Delaware Compares Nationally

Delaware's average cash price mirrors the national average. SGLT2 inhibitors as a class remain among the most expensive oral diabetes medications, with empagliflozin (Jardiance) priced comparably at roughly $580 to $630 per month [1]. Patients paying out-of-pocket in Delaware face the same sticker price whether they fill in Wilmington, Dover, or Rehoboth Beach.

A 2020 analysis in Diabetes Care found that SGLT2 inhibitor out-of-pocket costs were a primary driver of medication non-adherence, with patients facing monthly costs above $50 being 28% more likely to discontinue therapy within 12 months [2]. That finding makes Delaware savings strategies especially important for anyone prescribed this drug.

Delaware Medicaid Coverage for Farxiga

Delaware Medicaid covers Farxiga, but requires prior authorization (PA). Your prescriber must document that you meet specific clinical criteria before the state will approve the claim.

Prior Authorization Requirements

Delaware's Medicaid preferred drug list (PDL) classifies SGLT2 inhibitors as non-preferred agents requiring PA. In practice, this means the prescriber must show at least one of the following: a diagnosis of type 2 diabetes with inadequate glycemic control on metformin, a heart failure with reduced ejection fraction (HFrEF) diagnosis, or stage 3-4 chronic kidney disease (CKD) meeting the label indication.

The landmark DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [3]. That evidence base strengthens PA approval odds for heart failure indications specifically.

Tips for Faster PA Approval

Submit the PA request with an ICD-10 code matching the FDA-approved indication (E11.65 for type 2 diabetes with hyperglycemia, I50.2x for systolic heart failure, or N18.3/N18.4 for CKD stages 3-4). Include recent lab values: HbA1c for diabetes, ejection fraction for HF, or eGFR for CKD. Most Delaware Medicaid PA decisions arrive within 24 to 72 hours.

Patients denied on initial PA can appeal. Delaware Medicaid allows a fair hearing within 90 days of denial, and the prescriber can file an expedited appeal if the patient faces clinical harm from delay.

Private Insurance Coverage in Delaware

Most commercial plans in Delaware cover Farxiga on formulary, though tier placement and cost-sharing vary widely. The drug sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) for the majority of Delaware employer-sponsored and marketplace plans.

Major Insurers Operating in Delaware

Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare are the three largest commercial carriers in the state. Highmark BCBS of Delaware typically places Farxiga on Tier 3 with a $40 to $75 copay after deductible. Aetna and UnitedHealthcare formularies vary by employer group but generally require step therapy through metformin before approving SGLT2 inhibitor coverage.

Medicare Part D in Delaware

Medicare Part D plans cover Farxiga for approved indications, though enrollees should expect Tier 3 or Tier 4 placement. Under the Inflation Reduction Act provisions fully phased in by 2025, Medicare Part D out-of-pocket costs for all covered drugs are capped at $2,000 per year [4]. For a Delaware Medicare beneficiary taking Farxiga alone, this cap could reduce effective monthly costs significantly once the annual threshold is met.

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the risk of a sustained decline in eGFR of at least 50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001), leading to expanded CKD coverage across payers [5]. Delaware insurers have increasingly approved Farxiga for CKD since that 2020 data readout.

The AstraZeneca Savings Card: How It Works in Delaware

AstraZeneca offers a manufacturer copay savings card that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card is accepted at all major Delaware pharmacies.

Eligibility Rules

You qualify if you have commercial (private) insurance. You do not qualify if your coverage comes from Medicare, Medicaid, TRICARE, or any other federal or state government program. The card covers up to a set dollar amount per fill (typically up to $400 in savings per 30-day supply), and there is usually an annual maximum.

How to Activate

Patients can download the card from the AstraZeneca website or receive one from their prescriber. Present it at the pharmacy counter alongside your insurance card. The pharmacist runs both cards, and the savings card covers whatever copay or coinsurance remains after insurance processes the claim.

Limitations to Know

The savings card does not apply to the deductible on high-deductible health plans (HDHPs) in some cases, depending on plan rules around accumulator adjustment programs. Some Delaware employers use copay accumulator programs that prevent manufacturer card payments from counting toward your annual deductible or out-of-pocket maximum. Ask your HR department or call the number on your insurance card to confirm.

Compounded Dapagliflozin in Delaware

Compounded dapagliflozin is available in Delaware through licensed 503A compounding pharmacies. This is legal under federal law (Section 503A of the Food, Drug, and Cosmetic Act) when a prescriber writes a patient-specific prescription and the pharmacy holds a valid Delaware Board of Pharmacy license [6].

What Compounding Means for Price

Compounded versions of dapagliflozin can cost substantially less than brand Farxiga. Some 503A pharmacies advertise compounded SGLT2 inhibitor formulations at a fraction of the brand price, though exact pricing depends on the pharmacy, formulation, and quantity.

Quality and Regulatory Considerations

Compounded drugs are not FDA-approved products. They do not undergo the same manufacturing oversight, bioequivalence testing, or stability testing that commercial tablets receive. The FDA's guidance on compounding requires 503A pharmacies to compound only in response to individual prescriptions and prohibits large-scale manufacturing without a 503B outsourcing facility registration.

Delaware patients considering compounded dapagliflozin should verify that the pharmacy holds current licensure with the Delaware Board of Pharmacy. Ask whether the pharmacy conducts third-party potency and sterility testing on its oral solid-dose compounds. The American College of Cardiology (ACC) and American Diabetes Association (ADA) have not issued position statements endorsing compounded SGLT2 inhibitors as substitutes for FDA-approved products.

Telehealth Access to Farxiga in Delaware

Delaware permits telehealth prescribing of Farxiga. A licensed prescriber can evaluate you via video or audio visit and send the prescription electronically to any Delaware pharmacy.

Delaware Telehealth Law

Delaware's telehealth parity law (Title 18, Section 3370) requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means a telehealth consultation to obtain a Farxiga prescription should carry the same copay as an office visit under most Delaware plans.

How HealthRX Telehealth Works

HealthRX connects Delaware patients with licensed prescribers who can evaluate whether dapagliflozin is appropriate based on your medical history, labs, and current medications. The prescriber can order baseline labs (metabolic panel, eGFR, HbA1c) through a local Delaware lab and send the prescription to your preferred pharmacy once clinical criteria are met.

The ADA's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for type 2 diabetes patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c [7]. A telehealth prescriber in Delaware follows these same guidelines.

Strategies to Lower Your Farxiga Cost in Delaware

Reducing what you pay for Farxiga in Delaware depends on your insurance status. Here are the primary options ranked by potential savings.

For Commercially Insured Patients

1. AstraZeneca savings card. Can reduce copay to $0 per fill.
2. Formulary exception request. If your plan places Farxiga on a high tier, your prescriber can request a tier exception citing clinical necessity.
3. Mail-order pharmacy. Some Delaware plans offer lower copays for 90-day mail-order fills compared to 30-day retail fills.

For Uninsured or Underinsured Patients

1. AstraZeneca patient assistance program (AZ&Me). Provides free Farxiga to patients with household income at or below 300% of the federal poverty level who lack prescription coverage.
2. Compounded dapagliflozin. Available through Delaware-licensed 503A pharmacies at lower cost.
3. Pharmacy discount cards. Programs like GoodRx or RxSaver may reduce cash price by 10 to 20%, though savings on patent-protected brands are typically modest.

For Medicare Beneficiaries

1. Part D plan comparison. Use Medicare.gov's plan finder tool during open enrollment to compare Farxiga tier placement and copay across Delaware Part D plans.
2. Extra Help (Low-Income Subsidy). Delaware residents with limited income and resources may qualify for Medicare Extra Help, which can reduce Part D copays to $0 to $11 per fill.
3. $2,000 annual cap. The Inflation Reduction Act cap means total out-of-pocket Part D spending (including Farxiga) will not exceed $2,000 per calendar year [4].

Clinical Context: Why Dapagliflozin Costs What It Does

Farxiga's pricing reflects a drug with three distinct FDA-approved indications and a large evidence base. Understanding the clinical value helps frame the cost discussion.

Heart Failure Evidence

In DAPA-HF (N=4,744), dapagliflozin 10 mg reduced the primary composite endpoint of cardiovascular death or worsening heart failure by 26% in patients with HFrEF (LVEF ≤ 40%), regardless of diabetes status [3]. The number needed to treat (NNT) was 21 over a median 18.2 months. The European Society of Cardiology now lists SGLT2 inhibitors as a Class I recommendation for HFrEF [8].

Dr. John McMurray, principal investigator of DAPA-HF, stated: "The benefits of dapagliflozin were consistent across all prespecified subgroups, including patients without diabetes, which was a first for this drug class" [3].

Chronic Kidney Disease Evidence

DAPA-CKD (N=4,304) demonstrated that dapagliflozin reduced the composite renal endpoint by 39% in patients with CKD stages 2 through 4 and urinary albumin-to-creatinine ratio 200 to 5,000 mg/g, with or without type 2 diabetes [5]. The trial was stopped early for efficacy at a median follow-up of 2.4 years. The 2024 KDIGO guidelines now recommend SGLT2 inhibitors for CKD patients with eGFR ≥ 20 mL/min/1.73 m² [9].

Type 2 Diabetes Glycemic Data

In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin 10 mg reduced HbA1c by 0.42% versus placebo at 48 months and lowered the rate of hospitalization for heart failure by 27% (HR 0.73; 95% CI 0.61 to 0.88) in patients with type 2 diabetes and atherosclerotic cardiovascular disease or multiple risk factors [10].

The ADA's 2024 Standards of Care specifically state: "For patients with type 2 diabetes and established heart failure or chronic kidney disease, an SGLT2 inhibitor with demonstrated benefit is recommended regardless of HbA1c" [7].

Monitoring and Safety Costs to Factor In

Farxiga requires baseline and periodic lab monitoring that adds to total treatment cost. Delaware lab pricing varies by facility.

Required Labs

Before starting dapagliflozin, prescribers should order a basic metabolic panel (eGFR, potassium, bicarbonate), fasting glucose or HbA1c, and urinalysis. Follow-up labs are recommended at 1 to 3 months and then every 6 to 12 months [1].

Common Side Effects to Watch

The most frequent adverse events in clinical trials include genital mycotic infections (occurring in approximately 5 to 7% of women and 2 to 3% of men), urinary tract infections, and volume depletion symptoms such as dizziness or hypotension [1]. Rare but serious risks include diabetic ketoacidosis (DKA), which can occur even with normal blood glucose levels, and Fournier's gangrene. The FDA issued a safety communication in 2018 regarding SGLT2 inhibitors and Fournier's gangrene based on post-marketing reports [11].

Patients prescribed Farxiga should have a sick-day action plan: hold the medication during acute illness, surgery, or prolonged fasting to reduce DKA risk. This costs nothing but requires clear patient education at the prescribing visit.